A Randomized, Double-Blind, Placebo-Controlled, Phase I Trial Evaluating the Pharmacokinetics, Safety and Preliminary Efficacy of EP-104IAR (Long-Acting Fluticasone Propionate) in Patients With Osteoarthritis of the Knee

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Phase I Trial Evaluating the Pharmacokinetics, Safety and Preliminary Efficacy of EP-104IAR (Long-Acting Fluticasone Propionate) in Patients With Osteoarthritis of the Knee

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 24 Mar 2017

At a glance

  • Drugs Fluticasone propionate (Primary)
  • Indications Osteoarthritis
  • Focus Adverse reactions; Pharmacokinetics
  • Acronyms STEPUP
  • Sponsors Eupraxia Pharmaceuticals
  • Most Recent Events

    • 20 Mar 2017 Planned End Date changed from 1 Mar 2017 to 1 Dec 2017.
    • 20 Mar 2017 Planned primary completion date changed from 1 Mar 2017 to 1 Dec 2017.
    • 20 Mar 2017 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top